You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

OSIMERTINIB MESYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for osimertinib mesylate and what is the scope of freedom to operate?

Osimertinib mesylate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has one hundred and seventy-six patent family members in forty-three countries.

There are two drug master file entries for osimertinib mesylate. One supplier is listed for this compound. There is one tentative approval for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OSIMERTINIB MESYLATE
Generic Entry Date for OSIMERTINIB MESYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OSIMERTINIB MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sichuan Baili Pharmaceutical Co., Ltd.Phase 2
Klus Pharma Inc.Phase 2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Phase 2

See all OSIMERTINIB MESYLATE clinical trials

Generic filers with tentative approvals for OSIMERTINIB MESYLATE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up80MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up40MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for OSIMERTINIB MESYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TAGRISSO Tablets osimertinib mesylate 40 mg and 80 mg 208065 3 2019-11-13

US Patents and Regulatory Information for OSIMERTINIB MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OSIMERTINIB MESYLATE

Country Patent Number Title Estimated Expiration
Canada 2843109 DERIVES DE 2-(ANILINO 2,4,5-SUBSTITUE)PYRIMIDINE UTILISES COMME MODULATEURS DE L'EGFR UTILES POUR LE TRAITEMENT D'UN CANCER (2 -(2,4,5-SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER) ⤷  Sign Up
Poland 3009431 ⤷  Sign Up
European Patent Office 2736895 DERUVES DE 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMME MODULATUERS DU EGFR UTILES DANS LE TRAITEMENT DU CANCER (2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER) ⤷  Sign Up
Ecuador SP13013033 DERIVADOS DE 2-(2,4,5-ANILINO SUSTITUIDO)PIRIMIDINA COMO MODULADORES DE EGFR ÚTILES PARA EL TRATAMIENTO DEL CÁNCER ⤷  Sign Up
Japan 5977779 ⤷  Sign Up
Croatia P20211682 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OSIMERTINIB MESYLATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1848414 300824 Netherlands ⤷  Sign Up PRODUCT NAME: OSIMERTINIB (TAGRISSO); REGISTRATION NO/DATE: EU/1/16/1086 20160204
1848414 C 2016 026 Romania ⤷  Sign Up PRODUCT NAME: OSIMERTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1086; DATE OF NATIONAL AUTHORISATION: 20160202; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1086; DATE OF FIRST AUTHORISATION IN EEA: 20160202
1848414 CA 2016 00033 Denmark ⤷  Sign Up PRODUCT NAME: OSIMERTINIB; REG. NO/DATE: EU/1/16/1086/001-0002 20160204
1848414 93160 Luxembourg ⤷  Sign Up PRODUCT NAME: OSIMERTINIB (TAGRISSO); FIRST REGISTRATION DATE: 20160204
1848414 132016000078445 Italy ⤷  Sign Up PRODUCT NAME: OSIMERTINIB(TAGRISSO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1086, 20160204
1848414 122016000056 Germany ⤷  Sign Up PRODUCT NAME: OSIMERTINIB (TAGRISSO); REGISTRATION NO/DATE: EU/1/16/1086 20160202
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.